Mucosis B.V.
Meditech Center
L.J. Zielstraweg 1
9713 GX Groningen
The Netherlands
Trade Register / KvK: 02096219
Mucosis’s mission is to discover and develop mucosal vaccines for the prevention and treatment of infectious diseases. It is our goal to transform excellent research into novel high-value vaccines which serve patients in need of an efficacious therapy and improved patient convenience.
16.05.13 Mucosis presents preclinical data demonstrating protection by its intranasal SynGEM® RSV vaccine candidate
more >
08.10.12 Mucosis signs Research and License Option Agreement with Crucell
more >
25.09.12 ExpreS²ion, Mucosis, and University of Copenhagen receive Eurostars grant
more >
18.09.12 Mucosis Appoints Thomas Johnston to CEO
more >
10.05.12 Mucosis announces positive proof-of-concept data for Mimopath® platform in humans
more >
03.05.12 Mucosis announces publication of preclinical data demonstrating...
more >
15.11.11 Mucosis announces new scientific advisory board
more >
17.05.11 Mucosis appoints Thomas Johnston as Chief Business Officer
more >